An encore for the repeats: new insights into an old genetic variant. by Krausz, Csilla Gabriella
An Encore for the Repeats: New Insights into an Old
Genetic Variant
Csilla Krausz
Sexual Medicine and Andrology Unit, Department of Clinical Physiopathology, Medical Faculty,
University of Florence, 50139 50121 Florence, Italy
Throughout the human genome there are trinucleotiderepeat sequences susceptible to either expansion or
contraction during replication, giving rise to length poly-
morphisms in the general population. The polymorphic
CAG repeat, which encodes an uninterrupted polyglu-
tamine (polyQ) tract in theN-terminal transactivation do-
main of the androgen receptor (AR), is the most exten-
sively studied genetic variant in individuals with disorders
of the male reproductive system.
Despite an impressive number of studies, the patho-
genic role of this polymorphism and its clinical relevance
are still a matter of debate. Although a recent meta-anal-
ysis of 33 publications (1) supports a pathogenetic role for
longer polyQ length in male infertility, the authors con-
clude their work stating that there is a need for new, well-
designed studies (1). In fact, available data do not allowus
to establish what range of AR-CAG repeat lengths pre-
disposes impaired sperm production or to estimate the
entity of the associated risk (1). Similar to other genetic
variants, the literature related toCAGrepeats suffers from
an abundance in conflicting case-control association stud-
ies and a paucity of functional data (2). There are several
plausible explanations for these apparent controversies,
mostly related to: 1) poor study design (inappropriate se-
lection of patients and controls, particularly with respect
to their phenotype and their ethnic/geographic origin, and
underpowered size of the study population); and 2) in-
trinsic complexity of the interaction between the AR and
its endogenous/environmental ligands. An additional in-
tricacy derives from the presence of another polymorphic
trinucleotide repeat, (GGN)n, in the first exon of the AR
gene, which may modulate the functional effect of the
CAGrepeat length, stressing theneed for a combinedanal-
ysis of the two AR polymorphisms (3, 4).
It is commonly accepted that the length of the polyQ
tract influences the transactivation capacity of the recep-
tor in an inverse manner; that is, the longer the tract, the
lower the activity. To support this hypothesis, a clear neg-
ative impact on AR activity is documented in relationship
with pathological expansions of the repeat length (40 or
more), known as the Kennedy syndrome (5). This syn-
drome is characterized by spinobulbar muscular atrophy
and hypoandrogenism due to partial androgen insensitiv-
ity. On the other hand, controversies still exist about the
effect of variations in polyQ within the normal polymor-
phic range. The normal distribution of the (CAG)n is re-
ported as 6–39 repeats, with a median of 21–22 in White
Caucasian, 19–20 in African-American, 22–23 in Asian,
and 23 in Hispanic populations. Clinical observations
showing a linear correlation between testosterone level
and CAG repeat length support the notion of a functional
effect of the polymorphism within the normal range. In
fact, increased circulating testosterone and estradiol levels
in men with a higher number of CAG repeats can be con-
sidered as a compensatorymechanism aimed to overcome
the weaker AR activity (6, 7). However, such a linear cor-
relation has not been clearly demonstrated by in vitro ex-
periments. The first two functional studies reported that
the longest tract (Q31)displayed loweractivitywhencom-
pared with the shortest one (Q15). However, no signifi-
cant differences were observed by comparing these two
types of alleles to an intermediate number of CAG repeats
(20 or 24) (8, 9). Quite strikingly, two recent articles pro-
vided evidence for the lack of a stepwise reduction in ac-
tivity with increasing CAG length across the polymorphic
ISSN Print 0021-972X ISSN Online 1945-7197
Printed in U.S.A.
Copyright © 2012 by The Endocrine Society
doi: 10.1210/jc.2012-1130 Received January 17, 2012. Accepted January 19, 2012.
For article see page E393
Abbreviations: AR, Androgen receptor; polyQ, polyglutamine.
S P E C I A L F E A T U R E
E d i t o r i a l
764 jcem.endojournals.org J Clin Endocrinol Metab, March 2012, 97(3):764–767
range (10, 11).The reporter geneassaywith threedifferent
CAG lengths (16, 22, and 28) has indeed shown the high-
estARactivity in the presence of 22CAGrepeats (10). The
other study, performed in a human prostate tumor cell
model, has provided mechanistic insights into how both
increased and decreased polyQ allele length may nega-
tively affect receptor function (11).This studyhas revealed
a critical polyglutamine size (Q16-Q29) for optimal an-
drogen-induced AR signaling, which corresponds to 91–
99% of AR alleles within different ethnic groups. These
novel in vitro findings have introduced a new concept for
the analysis of AR-CAG repeat length in relationship to
AR-relateddiseases, indicating that linear regressionmod-
els are likely to be inappropriate.
In this issue of the JCEM, Davis-Dao et al. (12) provide
strong evidence for the need of a radical improvement in
the study design used to establish the relationship between
CAG repeat length and disease phenotypes. The study has
focused on cryptorchidism, a well-known androgen-de-
pendent disease. Both clinical evidence (cryptorchidism in
subjects affectedby androgen resistance) and animalmod-
els clearly demonstrate that testosterone is one of the ma-
jor hormonal regulators of testis descent (13). Therefore,
it is expected that variations in the transactivation activity
of AR, especially a longer polyQ tract, may be responsible
for nonsyndromic testicular maldescent. Despite this pre-
diction, the literature had unanimously dismissed long
CAG repeat length as a risk factor for cryptorchidism (3,
4, 14–16). Now, 5 yr after the last published study on this
topic, Davis-Dao et al. (12) adopt an innovative study
design and a distinct analytical model. For the first time,
patient recruitment is performed in a clinical context—
boys undergoing orchidopexy—which allows the precise
and unequivocal definition of the cryptorchid phenotype
and of comorbidities. All previous studies have included
adult men with a history of cryptorchidism, and thus con-
siderable difficulties were encountered in providing a rig-
orous phenotypic characterization. Importantly, in all
previous investigations, patients with associated inguinal
hernia were systematically excluded or not recorded. In
the study of Davis-Dao et al. (12), these cases belong to
the most relevant subgroup among which CAG repeat
length seems to be of clinical relevance. Another pecu-
liarity concerns the control group, which, instead of
unaffected unrelated subjects, refers to the second un-
transmitted maternal CAG allele. The comparison of
cases’ alleles to their mothers’ second not-transmitted
alleles is based on the transmission/disequilibrium test
for an X-linked marker in males and allows avoidance
of population stratification that can be an important
bias in admixed populations (17).
The major finding of the study is the unexpected asso-
ciation between shorter CAG repeats (CAG  19 vs.
CAG 20) and cryptorchidism risk, which was restricted
to those cases presenting comorbidities (especially ingui-
nal hernia). Among 127 patients, 64 have shown inguinal
hernia as the sole comorbidity,whereas sevenhad inguinal
hernia with other comorbidities (morbid obesity, hypos-
padias, micropenis, etc.). When considering all cryp-
torchid cases with any type of comorbidities (n  83), a
significant “protective” role of CAG repeats of 20 was
identified with an odds ratio of 0.35 (95% confidence
interval, 0.16–0.78). This association was even stronger
in the subgroup of subjects with bilateral cryptorchidism
[CAG 19 vs. CAG 20, odds ratio 0.09 (95% con-
fidence interval, 0.010–0.78)]. However, due to the rel-
atively small sample size of this subgroup (n  25), this
finding needs to be interpreted with caution. The intrigu-
ing clinical observation showing an association between
the shorter polyQ tract (considered the more active recep-
tor) and cryptorchidismwith comorbidities highlights the
complexity of this issue.
First of all, these results do not seem to fit with any of
the twopredictedAR-CAGtractmodels basedon the clas-
sical genomic pathway: 1) the inverse relationship be-
tween CAG number and AR activity; and 2) the “optimal
range” hypothesis predicting an altered function for re-
ceptors with both shorter and longer polyQ tract with
respect to the functionally critical range. To explain the
apparent paradox of the observed association between a
more active AR and the anomaly of an androgen-depen-
dent process,Davis-Dao et al. (12) speculate onan indirect
effect of polyQ length via alternative “nongenomic” sig-
naling pathways. According to their hypothesis, the re-
duced testosterone level—typically observed in men with
shorter polyQ—may lead to a suboptimal signaling of a
hypothetical nongenomic pathway involved in testis de-
scent. This hypothesis appears to be particularly attractive
in light of those studies demonstrating that cell growthand
antiapoptotic actions of androgens could be dissociated
from the transcriptional activity of the AR. Several au-
thors have reported that bothMAPK and PI3K/Akt path-
ways can be activated by the AR in cancer cell lines, thus
promoting cell proliferation as a consequence of rapid
“nongenomic action” (for review, see Refs. 18 and 19).
The most recent evidence suggests that the gubernaculum
actually acquires specific growth properties similar to an
embryonic limb bud (20). The primary hormone regulat-
ing transabdominal descent is insulin-like hormone 3 and
it is responsible for the “swelling reaction” of the guber-
naculum,whereas the secondphase is highlydependent on
testosterone action. However, recent experiments in ro-
dents indicate an intimate interplay between the two hor-
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mones during the entire process of testis descent (for re-
view, see Ref. 13). The swelling reaction anchors the testis
to the future inguinal canal. During the second, inguino-
scrotal phase of descent, the gubernaculum changes from
a relatively inert, static structure ending in the inguinal
muscles into an elongating, migrating organ. It has been
proposed that androgens trigger the ligamentous guber-
naculum to become an outgrowth like a limb bud, al-
though theunderlyingmechanism remains unknown (21).
In humans, the role of an indirect androgen action via the
genitofemoral nerve is not substantiated (13); therefore, it
is more likely that testosterone acts directly on the guber-
nacular growth (22), through the classical AR (cytoplas-
mic ormembrane-associated) or othermembraneproteins
still to be characterized (18). It would therefore be inter-
esting to explore whether androgen-induced nongenomic
pathways play a significant role in the proliferation of the
gubernacular cells. If this turns out to be the case, an in-
sight on the mechanisms involved in testis maldescent
caused by reduced testosterone levels associated with
short CAG tracts will be available.
Additional questions need specific attention, such as
the intriguingAR-CAG repeat link between testis maldes-
cent and inguinal hernia. Because both inguinoscrotal de-
scent and inguinal closure are mediated by androgens,
common genetic factors may be implicated in both path-
ological conditions. Given that cryptorchidism is a mul-
tifactorial, complex disease with a large spectrum of clin-
ical presentation (13, 23), it is highly likely that distinct
genetic anomalies are responsible for different types of
testicular maldescent. Consequently, the apparent dis-
crepancies with prior studies are likely to derive from the
different inclusion criteria adopted by Davis-Dao et al.
(12). Future large case-control association studies focus-
ing on different phenotypic subgroups (with and without
inguinal hernia, unilateral and bilateral cases, etc.) will
likely answer this question. The study by Davis-Dao et al.
(12) indicates adisadvantageonly in the caseof shortCAG
repeats; however, upcoming investigations will probably
shed light on whether the “optimal range” hypothesis can
be applied also to this specific pathological context. In
fact, the stratified analysis of nearly 4000 subjects, in-
cluded in articles dealing with male infertility and AR-
CAG length, has provided clinical evidence for the poten-
tial benefit of a CAG range corresponding to 22–23
triplets in spermatogenesis (24). However, it must be
taken into consideration that this specific rangemaynotbe
the same across different ethnic groups andmay even vary
in different tissues because the effect of polyQ repeat on
transactivation is cell specific, presumably due to distinct
profiles of coregulator proteins (11). Moreover, it is pos-
sible that spermatogenesis, more than the process of testis
descent, depends predominantly on the genomic action of
androgens, and thus on the direct consequence of theCAG
lengthon transactivation.Clearly,more functional studies
are needed for the interpretation of clinical data in differ-
ent types of androgen-dependent diseases.
After a long period of “quiescence” concerning the role
of the AR-CAG tract in cryptorchidism, the study by Da-
vis-Dao et al. (12) represents a strong stimulus for further
clinical and basic investigations. In addition, this article
opens new avenues toward the analysis of other AR-re-
lated diseases, which are likely to provide similar unex-
pected findings.
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